How many hospitals have signed three-year contracts with AI vendors, only to discover the system can't handle their PACS workflows or explain why it flagged a critical finding? It happens more often than most hospital executives care to admit. In my experience deploying AI radiology systems across hospital networks at Databoost Sdn Bhd, I've watched procurement teams make the same mistakes repeatedly — and the stakes are clinical safety, not just budget overruns.
The difference between a vendor proposal that will transform your radiology department and one that will languish in a storage server comes down to five red flags. These aren't subjective preferences. They're the hard technical and clinical markers that separate systems built for deployment from systems built for demos.
Red Flag #1: "We Don't Include Explainability — It Slows the Model Down"
This claim appears in roughly 40% of vendor pitches I review. It's wrong. When Fractify detects a potential intracranial hemorrhage or a tension pneumothorax on a brain CT, every radiologist who integrates the output into their workflow asks the same question: Why did the system flag this? Not later. Not in a separate report. In the moment of clinical decision-making.
Explainability through Grad-CAM heatmaps, attention maps, or decision trees adds 20–50ms to inference latency in modern architectures. This is negligible compared to the radiologist's reading time. If a vendor tells you explainability is impossible or impractical, they've either built their model poorly or they're hiding something. Radiologists need to trust the system, and trust requires understanding.
Honestly, I'd push harder on this in any procurement meeting. Ask for a demo where the system flags a finding and shows you exactly where on the image that finding appears. If the vendor fumbles that demo, move on.
Red Flag #2: High Accuracy Claims Without Independent Clinical Validation
Vendors love benchmark numbers. "98.5% accuracy on the ImageNet chest x-ray dataset." "97% sensitivity for pneumonia detection on our proprietary validation set." Benchmark accuracy is useful, but it tells you almost nothing about how the system will perform in your hospital.
Real-world radiology is messier than benchmark datasets. Patient motion, poor scout images, artifacts from metal implants, unusual body habitus, and prior studies that the algorithm wasn't trained on — these all degrade performance. A system trained on high-quality images from one hospital network often underperforms when deployed to a different network with different equipment, different technician protocols, and different patient populations.
When I was validating Fractify's models across eight hospital sites, we discovered that chest X-ray pathology detection rates varied by 3–5% depending on whether the imaging protocol included a lateral view. The algorithm learned to use bilateral input patterns, and single-view images threw it off. That's not a critical flaw — it's solvable through additional training data and retraining. But it's the kind of real-world complexity that never shows up in a press release.
Ask your vendor for: (1) peer-reviewed independent validation studies, (2) confidence intervals and failure mode analysis, (3) performance breakdowns by anatomic region and pathology type, (4) multisite validation data that includes hospitals demographically different from the vendor's training set. If they deflect, that's your answer.
Fractify's 97.9% accuracy on brain MRI tumor detection comes from multisite validation across five independent medical centers. The 97.7% bone fracture detection rate is published in peer-reviewed imaging journals with full methodology disclosure. These numbers matter because they're defensible in a court of law and in a medical malpractice case.
Red Flag #3: "PACS Integration Is on Our Roadmap"
dicom integration isn't a nice-to-have feature. It's the foundation of clinical deployment. DICOM is the standard for medical imaging across every modern hospital system worldwide, documented at https://www.dicomstandard.org. If a vendor's proposal positions PACS integration as a future roadmap item — something planned for version 2.0 or release 3.5 — that vendor doesn't understand hospital workflows.
Here's what happens when DICOM integration isn't native from day one: radiologists receive notifications that AI flagged a finding, they open a separate web portal to view the analysis, they switch back to their PACS system to document, they toggle between two screens, and within three weeks they stop using the AI system because the friction is unbearable. I've watched this play out at four hospitals.
Fractify's DICOM integration works at the gateway level — images flow from your PACS into Fractify's analysis engine, results populate back into your PACS as a structured report (HL7/FHIR formatted), and radiologists see the AI output within their existing reading workflow. Zero context switching. Zero retraining.
Good proposals specify DICOM compliance version, PACS server compatibility matrix, and network architecture diagrams. Vague proposals say "DICOM support" without technical detail. That's a red flag.
Red Flag #4: Generic Security Claims ("Enterprise-Grade," "Bank-Level Encryption")
Almost every vendor claims enterprise-grade security. Almost none of them can articulate what that means. "Bank-level encryption" doesn't exist as a technical specification. It's marketing language.
Enterprise healthcare AI systems need: (1) six-tier role-based access control (RBAC) so that a night-shift radiologist can't accidentally access morning staff's dashboards; (2) mandatory multi-factor authentication (MFA); (3) immutable audit logs that track who accessed what data and when; (4) session management with automatic timeout; (5) encryption in transit and at rest; (6) compliance with HIPAA and your regional data protection regulations.
When a vendor can't explain their RBAC model in detail, that's a red flag. When they say "all staff see all reports," that's a bigger red flag. Fractify's enterprise customers deploy six-tier access hierarchies — administrative roles, clinical director roles, senior radiologist roles, radiologist roles, technician roles, and audit roles — each with granular permissions down to the individual report level. Audit trails are immutable and queryable, and every access is logged with timestamp and reason.
Ask your vendor: "Walk me through your RBAC model. How many tiers do you support? Can I restrict a junior radiologist from accessing pediatric cases? Can I set up department-specific access?" If they stammer, move on.
Red Flag #5: Unrealistic Deployment Timelines (and No Change Management Plan)
"Go live in 8 weeks." This is a common promise, and it's almost always a red flag. Real AI radiology deployment in a hospital system takes 12–16 weeks of careful work: clinical protocol validation, staff training, integration testing with your specific PACS and EHR systems, change management, and a pilot phase.
Deployment isn't just technical. It's organizational. Radiologists need to understand how urgency scoring works — that Fractify flags a tension pneumothorax as urgent because it's life-threatening and requires immediate intervention, not because the algorithm is "alarmist." Technicians need to understand image quality thresholds. Administrators need to understand audit compliance.
Vendors who promise 8-week deployment either don't have a change management process, or they've cut it to near-nothing. That's how you end up with expensive software that staff resents and avoids.
A healthy vendor proposal includes: phased rollout (pilot → department expansion), documented change management, staff training schedules, and a 30–60 day support period post-launch. Fractify's deployment methodology allocates 4–6 weeks for the clinical validation phase alone, where radiologists work with the system, understand its capabilities and limitations, and sign off on clinical safety.
Expert Insight: Clinical Validation Is Non-Negotiable
Hospital AI procurement fails not because of technical limitations but because validation happens after deployment. The most rigorous vendors validate their systems across diverse patient populations and equipment configurations before the contract is signed. When we validated Fractify's models, we tested them on 50,000+ studies from eight independent sites — different scanners, different protocols, different clinical presentations. That's the standard you should demand. Any vendor unwilling to publish multisite validation data in a peer-reviewed journal is cutting corners on safety.
What Red Flags and Healthy Signals Look Like Side-by-Side
| Dimension | Red Flag ⚠️ | Healthy Signal ✓ |
|---|---|---|
| Explainability | "We don't include heatmaps; it slows inference" | Every finding includes Grad-CAM heatmap with <50ms latency |
| Validation Data | Accuracy claims from vendor's own benchmark dataset | Peer-reviewed multisite validation; published confidence intervals; independent test set |
| PACS Integration | "Coming in version 2.0" or "DICOM support available" | Native DICOM integration in release 1.0; HL7/FHIR output; specific PACS vendor compatibility matrix |
| Security | "Enterprise-grade security" / "Bank-level encryption" | 6-tier RBAC, mandatory MFA, immutable audit logs, 256-bit AES encryption, HIPAA compliance matrix |
| Deployment Timeline | 8 weeks go-live; minimal change management | 12–16 week phased rollout with clinical validation, staff training, and 30–60 day support |
| Accuracy Performance | 98.5% on a single benchmark dataset | 97.9% brain MRI detection; 97.7% fracture detection across multisite independent validation |
| Urgency Scoring | Model flags findings but doesn't differentiate urgency | 5-level urgency classification tied to clinical severity (immediate/urgent/routine/quality review/non-diagnostic) |
| Vendor Transparency | Vague answers about architecture; avoids technical depth | Detailed security, architecture, and validation documentation provided under NDA if needed |
What a Strong Vendor Proposal Should Include
Clinical Validation Documentation
Peer-reviewed studies, multisite independent validation data, confidence intervals for each pathology detected, failure mode analysis, performance stratified by patient demographics and imaging quality.
Technical Architecture Specification
DICOM gateway specs, PACS compatibility matrix, network topology, inference latency per modality, scalability (throughput at peak load), failover and redundancy architecture.
Security & Compliance Matrix
RBAC tiers (minimum 6), MFA implementation, audit logging spec, encryption (in-transit and at-rest), HIPAA compliance certification, regional data residency options, SOC 2 or equivalent audit.
Deployment & Change Management Plan
Phased rollout schedule, clinical validation protocol, staff training curriculum, integration testing plan, pilot duration (8–12 weeks), production support model (30–60 day SLA).
Model Explainability & Interpretation Guide
Heatmap generation for each finding, confidence scores, differential diagnosis suggestions (if trained on structured reports), failure case documentation, edge cases where the model is unreliable.
Modality & Pathology Coverage Roadmap
Which modalities are supported (chest X-ray, CT, MRI, dental X-ray, ultrasound?), which pathologies are detected with what accuracy, planned expansion timeline, dedicated research roadmap with publication goals.
What I'd Actually Do If I Were Reviewing Proposals Today
I genuinely haven't seen enough data to say definitively whether a vendor's success depends more on validation rigor or on deployment process maturity — I suspect both matter equally, but my experience leans heavily toward deployment. Hospitals with the best outcomes tend to be ones where the vendor committed to a 16-week phased rollout and the hospital leadership secured protected time for radiologist training.
My take: if I were evaluating AI radiology vendors today, I'd weight the evaluation 40% validation, 30% architecture, 20% deployment process, 10% price. Too many hospitals flip that weighting. They see a demo that impresses the radiologists and sign a contract without demanding the validation documentation or the security matrix. That's how you end up with a $500K contract for software that doesn't integrate with your PACS.
There's one honest caveat I'd add: if your hospital has a very small radiology department (3–5 radiologists) and you're not subject to strict regulatory auditing, some of these requirements might be overkill. A lean startup vendor without formal SOC 2 certification might still deliver value. But if you're a medium-to-large health system or if you're required to maintain regulatory compliance, every single red flag I've outlined above is non-negotiable.
In Sum: Trust the Checklist, Not the Demo
The five red flags above aren't new. They're the same issues that have plagued healthcare AI adoption for the past five years. Explainability, validation, DICOM integration, security rigor, and realistic timelines — these are the technical and organizational fundamentals. Vendors who can't articulate them clearly in writing usually can't deliver them in production.
When you're reviewing proposals, don't let a polished demo override your due diligence checklist. The best AI radiology system in the world, deployed poorly without clinical validation or security rigor, becomes a liability. Fractify exists because we obsessed over exactly these details — 97.9% accuracy means nothing if radiologists can't trust the system, DICOM integration comes on day one, and your audit team can verify every clinical decision the algorithm made.
Request the documentation. Push on the vague answers. If a vendor gets defensive about explainability or validation, that's your signal. The right partner will give you detailed specifications in writing and will back them up with peer-reviewed evidence.
Frequently Asked Questions
What's the difference between a vendor's claimed accuracy and real-world accuracy?
Claimed accuracy typically comes from a single vendor-controlled dataset where imaging quality is consistent, patient demographics are homogeneous, and edge cases are minimal. Real-world accuracy accounts for equipment variation, staff expertise differences, diverse patient populations, and complex cases not in the training data. Demand multisite independent validation with confidence intervals — that's your real-world number.
If a vendor doesn't have DICOM integration yet, is it a dealbreaker?
Yes, functionally. DICOM integration is table stakes for any AI system that radiologists will use daily. Without it, the system requires separate workflows, which hospitals abandon within weeks. If a vendor says "coming soon," ask them to commit to a specific release date in the contract with financial penalties for delay. Most won't commit, which tells you something.
How do I evaluate an AI vendor's explainability claims?
Ask for a live demo where the system flags a specific pathology (brain tumor, fracture, pneumothorax) and shows you exactly where on the image that finding appears using Grad-CAM or attention heatmaps. If the vendor can't produce that in under 2 minutes, their explainability isn't production-ready. Bonus: ask them to show you a false positive case and explain why the model misclassified it.
What should I ask about in a security review?
Ask for a detailed RBAC specification (how many tiers, what permissions per tier), MFA implementation details, immutable audit log examples, encryption algorithms (AES-256 minimum), and HIPAA compliance certification. Ask who has access to the admin panel and whether role-based restrictions prevent privilege escalation. If they can't provide written documentation, that's a red flag.
Is 8-week deployment actually possible?
Technically possible but usually not wisely done. Real deployment includes clinical protocol validation (4–6 weeks), staff training, PACS integration testing, change management, and a pilot phase. Vendors promising 8 weeks typically skip one or more of these steps. If your hospital moves faster, that's fine — just make sure you're not cutting clinical validation or security hardening.
How do I benchmark a vendor's accuracy against Fractify?
Ask for apples-to-apples comparison: same imaging modality, same pathology, same validation methodology. Fractify's 97.9% brain MRI tumor detection and 97.7% bone fracture detection are published in peer-reviewed journals with full methods disclosure. Any vendor claiming higher accuracy should provide equivalent peer-reviewed evidence. If they cite only press releases, that's a red flag.
What happens if the vendor goes out of business after I sign a contract?
This is rare but worth asking about. Request contractual guarantees around source code escrow (your hospital gets access to code if the vendor fails), API stability (versions won't break suddenly), and transition support (vendor commits to helping you migrate to an alternative system). Good vendors will agree to these terms. If they won't discuss it, that's telling.
Should I trust a vendor's claims about their research roadmap?
No. Ask instead what they've published in the past 18 months in peer-reviewed journals. Publication history is predictive of future research output. If a vendor has published nothing, their research roadmap is aspirational, not committal. Fractify publishes validation studies annually because rigorous research is core to our development process, not a marketing afterthought.
See Fractify working on your own scans — live demo takes 15 minutes.
Request a Free Demo →